ISRCTN01207094已完成不适用
Autologous stem cell transplantation for patients with AL amyloidosis. A prospective phase II study
Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)0 个研究点目标入组 70 人开始时间: 2010年11月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 18-65 years incl.
- •2. Monoclonal Gammopathy of Undetermined Significance (MGUS), multiple myeloma stage I
- •3. Histologically documented systemic AL amyloidosis
- •4. Untreated or previously treated with maximal 3 courses of melphalan and prednisone
- •5. The patient must give informed consent according to the rules of the hospital
排除标准
- •1. Prior malignancies diagnosed less than 5 years ago, except non-melanoma skin tumours or stage 0 (in situ) cervical carcinoma
- •2. Patients with familial variants of systemic amyloidosis
- •3. Severe pulmonary, neurologic, psychiatric, cardiac, liver or metabolic disease not related to AL amyloidosis
研究者
相似试验
招募中
不适用
Autologous stem cell transplantation for the treatment of refractory Crohn*s disease: mechanisms of succesNL-OMON39547Sint Antonius Ziekenhuis15
已完成
2 期
pfront autologous stem cell transplantation for primaly peripheral T cell lymphomaALK-ngative Anaplastic large cell lymphoma(ALCL), Angioimmunoblastic T-cell lymphoma(AITL), Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)JPRN-UMIN000028831Tosei General Hospital Department of Hematology and Oncology19
进行中（未招募）
1 期
Controlled trial to assess low intensity autologous stem cell transplant in refractory Crohn's DiseaseEUCTR2017-002545-30-GBBarts Health NHS Trust99
已完成
不适用
autologous hematopoietic stem cell transplantation followed by reduced intensity allogeneic stem cell transplantation for relatively young patients with multiple myelomamultiple myelomaJPRN-UMIN000002533The university of Tokyo Hospital,department of hematology and oncology20
已完成
不适用
Autologous peripheral blood stem cell transplantation using Thiotepa, Carboplatin and Etoposide conditioning in patients with relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)JPRN-UMIN000026084agoya University Graduate School of Medicine10